Letter from the Editor #646
The EASD meeting was chock full of news about the latest drugs and new classes of medications. In one important...
Test Your Knowledge #646: Which answer is not an indication for ketone testing?
Which answer is not an indication for ketone testing?
Importance of Physical Activity Studies (pdf)
Show your patients this short list of some of the studies demonstrating...
Importance of Physical Activity Studies (pdf)
Importance of Physical Activity Studies (pdf)
Show your patients this short...
Omron HJ-323U USB Downloadable Pedometer
Omron HJ-323U USB Downloadable Pedometer
Type 2 Risk Tied to Short Sleep in Teens
Researchers found that less sleep for US teenagers meant a higher chance of insulin resistance. They suggest that increasing the amount of sleep teenagers get could protect them against diabetes. Karen Matthews, of the Department of Psychiatry at...
More Adults Use Mobile Phones, Tablets for Health Data
The number of adults using mobile phones and tablets for health information has risen exponentially from last year, according to a new study. The healthcare market research study shows that while online health activities are still primarily desktop...
Apple Juice Shows Obesity Benefits
A daily glass of cloudy apple juice may decrease body fat in obese people, compared to a control beverage, with greater effects noted in individuals with certain genetic profiles. Four weeks of drinking 750 mL per day glass of cloudy apple juice...
EASD: New EASD/ADA Position Paper Shifts Treatment Goals with 7 Key Points
A new position statement for treatment of type 2 diabetes treatment focuses on the individual patient rather than a "one number fits all" HbA1c target....
EASD: Increasing Physical Activity Slashes CV Events, Deaths by 66% for Type 2's
Higher levels of leisure-time physical activity cut the risk of cardiovascular and all-cause mortality in people with type 2 diabetes....
EASD: Once a Year Exenatide Introduced at EASD
Continuous long-term delivery of exenatide with Intarcia's osmotic mini-pump system allows optimal dose selection for improved glycemic control, ensures adherence, and improves patient tolerability....
EASD: Merck's Investigational Once-Weekly DPP-4 Inhibitor Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
Merck announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes....
EASD: Kidneys Tell of Heart Risk in Type 1 Diabetes
Researchers report that, for type 1 diabetes patients who have good glycemic control, renal function may predict their risk of developing heart disease....
EASD: SGLT-2 Demonstrates Reductions in Blood Pressure
Analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes....
EASD: SGLT-2 Added to Insulin Effective or Type 2's with CVD
First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease....
EASD: Findings Presented on New Insulin Sensitizing Agent for Treatment of Type 2 Diabetes
Researchers have identified a mitochondrial target through which insulin sensitizers achieve their anti-diabetic effects....
EASD: Lilly and Boehringer Ingelheim Present Data for Investigational Novel Basal Insulin Analog
Eli Lilly and Boehringer Ingelheim announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes....
Electronic Health Records Linked to Better Diabetes Outcomes
The use of an outpatient electronic health record (EHR) system, rolled out across 17 medical centers, was associated with improvements in clinical outcomes and health care utilization in a study population of nearly 170,000 people with...
Kidney Disease a Predictor of Mortality
Kidney disease is a significant predictor of all-cause mortality and end-stage renal disease (ESRD) in patients with and without hypertension or diabetes, according to two large meta-analyses....
Fewer Hypo's with New Degludec Insulin
Insulin degludec, an investigational insulin with a prolonged half-life and a reportedly flatter pharmacokinetic profile with fewer high and low levels, showed a modest hypoglycemic edge over insulin glargine in a 52-week head-to-head...
